23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs Blue Genes AI-Powered Pharmacogenetics

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

by 23andMe

Blue Genes AI-Powered Pharmacogenetics

by Blue Genes

AI Verdict

Tool A, 23andMe, focuses on providing direct-to-consumer genetic health risk information for specific conditions like hereditary thrombophilia, empowering individuals with insights for proactive health discussions. Tool B, Blue Genes, is an AI-powered pharmacogenetics platform designed for healthcare providers, offering real-time suggestions for alternative therapies based on pharmacogenomic data to support safer prescribing and reduce administrative burden. While both leverage genetic data, 23andMe is patient-centric for risk assessment, whereas Blue Genes is provider-centric for medication management.

Choose 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia if…

Choose 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia if you are an individual seeking direct-to-consumer genetic insights into your personal risk for developing harmful blood clots due to specific genetic variants (Factor V Leiden and Prothrombin G20210A). This tool is ideal for those who want to proactively discuss potential hereditary thrombophilia risks with their healthcare professionals and gain access to ancestry reports and educational resources.

View 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia →

Choose Blue Genes AI-Powered Pharmacogenetics if…

Choose Blue Genes AI-Powered Pharmacogenetics if you are a healthcare provider or part of a healthcare system looking to integrate pharmacogenomic data into your clinical decision-making process for safer prescribing. This tool is best suited for optimizing drug therapy, reducing administrative burden through AI-powered communication, and receiving real-time suggestions for alternative therapies based on a patient's genetic profile.

View Blue Genes AI-Powered Pharmacogenetics →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia	Blue Genes AI-Powered Pharmacogenetics
Pricing	$199	Not publicly available
Deployment	Cloud-based (for data access and reports), At-home kit (for sample collection)	Cloud-based
BAA Available	No AI-estimated	Unknown
FDA Status	1 AI-estimated	Exempt AI-estimated
HIPAA	No AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

23andMe offers a direct-to-consumer model with an at-home sample collection kit and personalized online reports, making it highly accessible for individual users. Blue Genes, while offering AI-powered chat for patient and provider communication, is primarily an enterprise solution integrated into clinical workflows, which may present a steeper learning curve for individual users outside of a clinical setting.

Clinical Value

Blue Genes AI-Powered Pharmacogenetics

Blue Genes provides real-time, AI-powered suggestions for alternative therapies based on pharmacogenomic data, directly impacting prescribing decisions and potentially improving patient safety and outcomes. 23andMe offers genetic health risk information for proactive health discussions, which is valuable, but does not offer real-time clinical decision support for treatment.

Pricing & Value

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

23andMe's pricing is transparent and publicly available, with various tiers catering to different needs, starting at $99 and going up to $499 for more comprehensive services. Blue Genes does not publicly disclose its pricing, making it difficult for potential customers to assess its value proposition without direct inquiry.

Enterprise Readiness

Blue Genes AI-Powered Pharmacogenetics

Blue Genes is designed for seamless integration with provider workflows, PBMs, and EMRs, and offers features like automated outreach and support for claim denials, indicating a strong focus on enterprise adoption and administrative efficiency. 23andMe is primarily a direct-to-consumer product, with less emphasis on enterprise-level integrations and administrative support.

Innovation

Blue Genes AI-Powered Pharmacogenetics

Blue Genes leverages AI for real-time, personalized pharmacogenetic recommendations and offers AI-powered voice and chat agents for patient and provider communication, representing a more advanced application of AI in clinical decision support. 23andMe's innovation lies in its direct-to-consumer model for genetic testing and health risk reporting, but its core technology is more established.

Support & Docs

Tie

Both tools offer educational resources. 23andMe provides educational resources for healthcare professionals and personalized online reports. Blue Genes offers instant support for common questions via chatbot and clear explanations of claim denials. Without more specific details on the breadth and depth of their documentation and support channels, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia	Blue Genes AI-Powered Pharmacogenetics
Name	23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia	Blue Genes AI-Powered Pharmacogenetics
Company	23andMe	Blue Genes
Primary Category	Clinical Decision Support & Reference, Lab & Diagnostics	Clinical Decision Support & Reference, Pharmacology & Dosing AI
Key Features	Detection of Factor V Leiden variant (F5 gene), Detection of Prothrombin G20210A variant (F2 gene), Direct-to-consumer saliva sample collection, Personalized online genetic health risk reports	AI-powered voice and chat agents for patient and provider communication, Real-time suggestions of clinically appropriate alternative therapies based on pharmacogenomic data, Automated outreach for genetic test kit reminders and guidance, Seamless integration with provider workflows, PBMs, and EMRs

Videos

Demos, reviews, and walkthroughs featuring 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia and Blue Genes AI-Powered Pharmacogenetics.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow and EHR system?

Blue Genes is designed for seamless integration with provider workflows, PBMs, and EMRs, offering real-time suggestions for alternative therapies based on pharmacogenomic data. This allows for immediate intervention before a prescription is filled, reducing administrative load. In contrast, 23andMe provides direct-to-consumer genetic health risk reports, which physicians would need to access and interpret separately for proactive health discussions, as it is not designed for direct EHR integration or real-time clinical decision support within a prescribing workflow.

What is the accuracy and sensitivity of each tool's genetic analysis?

23andMe's Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia uses qualitative genotyping to detect specific genetic variants (Factor V Leiden and Prothrombin G20210A) associated with an increased risk of blood clots. This test has been evaluated by the FDA for accuracy, reliability, and consumer comprehension. Blue Genes leverages AI-powered pharmacogenetics to identify ineffective or unsafe medications based on an individual's genetic profile, checking for drug-gene interactions for over 500 medications. While Blue Genes aims to cut adverse drug reactions by over 50%, specific accuracy and sensitivity metrics for its broad pharmacogenomic analysis are not detailed in the provided information.

Which specialties are these tools best suited for, and what clinical context do they provide?

23andMe's Hereditary Thrombophilia test is primarily relevant for hematology and laboratory medicine, offering insights into an individual's genetic predisposition to harmful blood clots for proactive health discussions. Blue Genes, as a pharmacogenetics solution, is well-suited for family medicine and internal medicine, providing real-time, AI-powered suggestions for alternative therapies to support safer prescribing and reduce adverse drug reactions across a wide range of medications. It can also be applied to pain management and GLP-1 therapy optimization.

What is the learning curve for physicians to effectively use each tool in their practice?

Blue Genes is designed to integrate seamlessly into existing clinical workflows and utilizes AI-powered voice and chat agents to provide real-time support and explanations, aiming to reduce administrative load and support better decision-making without requiring extensive additional time for patient education or follow-up. This suggests a lower learning curve for physicians as the system provides actionable insights directly. For 23andMe, physicians would need to understand how to interpret the direct-to-consumer genetic health risk reports and integrate these insights into their patient discussions and care plans, which may require a greater understanding of the specific genetic variants and their clinical implications.

What kind of support is available for physicians using these tools?

Blue Genes offers AI-powered voice and chat agents for both patients and providers, designed to deliver fast, accurate, and HIPAA-aware support at scale, including direct interaction with doctors to explain prescription claim denials and provide real-time suggestions for alternative therapies. They also have licensed PharmDs who use AI to provide rapid, informed answers and are available for more complex cases. The provided information for 23andMe highlights educational resources for healthcare professionals, but does not detail direct physician support channels for interpreting results or integrating them into practice.

Are there customer references or case studies available to demonstrate the value of these tools in a multi-site rollout?

Blue Genes has established partnerships with PBMs and health plans, and its technology is built for health systems and healthcare networks, indicating its suitability for scalable enterprise solutions and multi-site rollouts. They have announced collaborations with companies like RxSense and Liviniti to integrate pharmacogenomic insights into pharmacy benefit workflows and EMRs at scale. While 23andMe is a direct-to-consumer service, the provided information does not include details on multi-site rollout considerations or customer references for physician-led implementations.

More Comparisons

eCARTv5 Clinical Deterioration Suite (eCART) vs Google Med-PaLM 2

ChatGPT vs Google Med-PaLM 2

When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…

Brainomix 360 e-CTA vs Google Med-PaLM 2

DeepXray vs Google Med-PaLM 2

More matchups featuring 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia or Blue Genes AI-Powered Pharmacogenetics

Backers

Who funded each tool's parent company.